The probe is directed at all CAR-Ts currently ... positive lymphoma – in patients who had received both types of CAR-T therapy. The regulator highlighted the products by name, including Bristol- ...
A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...
TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...
A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...
Baird says Allogene Therapeutics’s (ALLO) cemacabtagene ansegedleucel data update is positive. The firm is “quite encouraged” by the update, ...
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell therapy that may bypass lymphodepletion, paving the way for a phase 1 trial in ...
Anixa Biosciences (ANIX) announced that it, along with its partner Moffitt Cancer Center, has received approval for an amendment to the ...
CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...
The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...
Like other CAR-Ts, Calibr's therapy is manufactured from a patient's own T-cells, which are harvested and genetically modified to fight cancer before being reintroduced into the body. However ...